ABT-737 displaces BIM from BCL-2’s BH3-binding pocket, subsequently activates BAX and induces mitochondrial permeability, ultimately leading to apoptosis.463,475,1167 ABT-737 has antitumor activity against hematologic and solid tumors, including CLL, lymphoma, and SCLC.475,1168,1169 In addition, ABT-737 exerts synergistic cytotoxicity with chemotherapy and radiotherapy.475 AZD0466, a novel BH3-mimetic inhibitor targeting BCL-XL and BCL-2, has potent antitumor activity in preclinical models of malignant pleural mesothelioma.1170. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.